Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Anti-IgE in Seasonal Allergic Rhinitis
NCT03019237Completed
- Sponsor
- Medical University of Vienna
- Start
- Nov 2012
- Primary completion
- May 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, double-blind trial of omalizumab in seasonal allergic rhinitis (SAR) (3 arms), sponsored by Medical University of Vienna. Primary endpoint: Change of allergen-specific IgE at 8 weeks. Started Nov 2012; status: completed.
02
Drugs
omalizumab
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT03019237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03019237.